NVP-BGT226

NVP-BGT226

CAT N°: 22142
Price:

From 60.00 51.00

NVP-BGT226 is an orally bioavailable dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR).{35140} It inhibits class I PI3Ks with EC50 values of 4, 63, and 38 nM for PI3K?, ?, and ? isoforms, respectively, in a filter binding assay. It binds to both class I and class III PI3Ks in a quantitative ELISA assay with EC50 values of 55.8 and 7.03 nM, for HsPI3K? and HsVps34, respectively.{35142} It decreases protein levels of phosphorylated mTOR and Akt, a downstream target of PI3K signaling.{36351} NVP-BGT226 inhibits the growth of squamous cell carcinoma cell lines, HONE-1, and a variant of HONE-1 resistant to cisplatin (Item No. 13119) with IC50 values of 7.4-27.8, 22.6, and 30.1 nM, respectively.{35138} It halts the cell cycle at the G0/G1 phase and induces autophagy. NVP-BGT226 (2.5 and 5 mg/kg daily for three weeks) inhibits tumor growth in a FaDu head and neck cancer mouse xenograft model.

We also advise you